INVESTABOT
Equity Research
XNAS · BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Biogen (BIIB) had 1 Form 144 pre-sale notice filed on 2026-08-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one filing…
TL;DR: Biogen's Q2 2026 earnings per share came in at $0.95, a figure that reflects roughly $164 million in acquired in-process R&D and milestone expenses. The real story is what's coming next: Q3 guidance signals that…
TL;DR: Biogen reported Q1 2026 revenue of $2.478B, up 1.9% from $2.431B a year ago, with GAAP diluted EPS of $2.15 and net income of $319.5M.
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 1 unique sellers · Institutional activity: not available - insufficient comparable institutions for the latest complete quarter.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 1, 2026 | Parini Michael | Chief Legal Officer | GRANT | 7,405 | — | — |
| August 4, 2026 | Minor Lloyd | — | SELL | -593 | $201 | ~$0.1M |
| August 3, 2026 | Minor Lloyd | — | SELL | -593 | $203 | ~$0.1M |
| June 9, 2026 | Hawkins William A | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Sherwin Stephen A | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Rowinsky Eric K | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Mantas Jesus B | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Langer Susan | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Patolawala Monish D | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Pangalos Menelas N | — | OPTION_EXERCISE | 2,370 | — | — |
| June 9, 2026 | Pangalos Menelas N | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Pangalos Menelas N | — | OPTION_EXERCISE | -2,370 | — | — |
| June 9, 2026 | Minor Lloyd | — | GRANT | 1,505 | — | — |
| June 9, 2026 | Freire Maria C | — | GRANT | 2,005 | — | — |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | OPTION_EXERCISE | 939 | — | — |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | TAX_WITHHOLD | -455 | $187 | ~$85K |
| May 1, 2026 | Keeney Adam | Head of Corporate Development | OPTION_EXERCISE | -939 | — | — |
| April 1, 2026 | Godbout Sean | Chief Accounting Officer | OPTION_EXERCISE | 181 | — | — |
| April 1, 2026 | Godbout Sean | Chief Accounting Officer | TAX_WITHHOLD | -54 | $184 | ~$10K |
| April 1, 2026 | Godbout Sean | Chief Accounting Officer | OPTION_EXERCISE | -181 | — | — |
| Date | Insider | Title | Relationship | Shares | Filing |
|---|---|---|---|---|---|
| August 12, 2026 | — | — | — | — | SEC |